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Menstrual cycle rhythmicity: 
metabolic patterns in healthy 
women
C. F. Draper1,3, K. Duisters2, B. Weger1, A. Chakrabarti1, A. C. Harms  3,4, L. Brennan5, 
T. Hankemeier3,4, L. Goulet1, T. Konz1, F. P. Martin1, S. Moco  1 & J. van der Greef3,4
The menstrual cycle is an essential life rhythm governed by interacting levels of progesterone, 
estradiol, follicular stimulating, and luteinizing hormones. To study metabolic changes, biofluids were 
collected at four timepoints in the menstrual cycle from 34 healthy, premenopausal women. Serum 
hormones, urinary luteinizing hormone and self-reported menstrual cycle timing were used for a 
5-phase cycle classification. Plasma and urine were analyzed using LC-MS and GC-MS for metabolomics 
and lipidomics; serum for clinical chemistries; and plasma for B vitamins using HPLC-FLD. Of 397 
metabolites and micronutrients tested, 208 were significantly (p < 0.05) changed and 71 reached the 
FDR 0.20 threshold showing rhythmicity in neurotransmitter precursors, glutathione metabolism, the 
urea cycle, 4-pyridoxic acid, and 25-OH vitamin D. In total, 39 amino acids and derivatives and 18 lipid 
species decreased (FDR < 0.20) in the luteal phase, possibly indicative of an anabolic state during the 
progesterone peak and recovery during menstruation and the follicular phase. The reduced metabolite 
levels observed may represent a time of vulnerability to hormone related health issues such as PMS 
and PMDD, in the setting of a healthy, rhythmic state. These results provide a foundation for further 
research on cyclic differences in nutrient-related metabolites and may form the basis of novel nutrition 
strategies for women.
The monthly menstrual cycle represents one of many physiological rhythms essential for life. The heartbeat and 
daily sleep-wake cycle represent obvious rhythms. Less obvious are the physiological processes inside the body 
such as the rhythmicity of the sex hormones that drive the menstrual cycle and others that regulate growth and 
metabolism1. These rhythms also interact with each other through synchronization of cellular activities with 
the external environment through feedback mechanisms that promote dynamic stability, such as the interac-
tion between circadian rhythms, sleep and the menstrual cycle2,3. Perturbations of the body’s rhythmic processes 
are associated with disorders4 such as disturbed circadian rhythmicity with premenstrual dysphoric disorder 
(PMDD)5 or abnormal expression of the circadian clock gene and spontaneous abortion6.
The first half of the menstrual cycle is comprised by the menstrual and follicular phases during which time 
estrogen levels are low (menstrual phase) and rise (follicular phase) and ends with the periovulatory phase in 
which follicular stimulating hormone (FSH) and luteinizing hormones (LH) peak. The second half of the cycle is 
comprised by the luteal (during which time estrogen level rises with a progesterone peak) and the pre-menstrual 
phases during which time estrogen and progesterone levels fall (Fig. 1)7–9). However, it is during this time that 
women experience worsening of chronic diseases such as diabetes and inflammatory bowel disease, bloating, 
poor sleep quality, and premenstrual syndrome (PMS) or PMDD10–18. Moreover, the luteal phase is also accompa-
nied by decreasing amino acid levels and elevated nitrogen utilization19,20. Women with PMS and PMDD have an 
increased appetite, food cravings and excess calorie intake which are associated with cyclical changes in serotonin 
during this period12,21–23. These biochemical changes suggest nutrient utilization is affected by changing sex hor-
mones between phases. The luteal phase of the menstrual cycle may be considered a normally stressed physiology 
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which amplifies differential responses between individuals to environmental stressors such as diet intake. These 
differential responses might predict future chronic health issues.
In order to characterize baseline metabolic rhythmicity in the menstrual cycle, advanced metabolomic profil-
ing, clinical and nutrient biochemistries were analyzed for rhythmic variations throughout a healthy menstrual 
cycle in 34 healthy women. Samples were analysed from five different phases of the menstrual cycle obtained 
from a previously published study19. The results are interpreted in light of metabolic differences that may repre-
sent vulnerability to sex hormone related disorders and nutritional needs, as well as diagnostic and therapeutic 
approaches that vary across the menstrual cycle (Fig. 2).
Results
Analysis of the plasma levels of estradiol, progesterone, luteal hormone and follicular stimulating hormone fol-
lowed the expected temporal concentration profiles of cycle phases, however, the estradiol concentration in the 
follicular phase was lower than the luteal phase peak (Supplementary Fig. 1 vs. Fig. 1). This variation may repre-
sent the small number of women in a narrow age range in this study.
The 4 sampling windows of the original study were timed to capture the menstrual (M), follicular (F), periovu-
lar (O), luteal (L) and pre-menstrual (P) phases of the cycle. All participants were observed during one monthly 
cycle. A total of 33, 31, 15, 27, and 11 samples were available for the M,F,O,L,P phases respectively; and 117 sam-
ples were available for analysis of all metabolites (Supplementary Table 1).
Since the overall research goal was to investigate menstrual cycle metabolic rhythmicity, it is natural to assess 
phase dynamics of individual biochemical species. To do so, calculated phase means of each biochemical species 
were compared, while taking the participant-specific nature of the data into account. Each phase-phase differ-
ence, or contrast, is tested for statistical significance before (p < 0.05) and after multiple testing control of the false 
discovery rate (q < 0.20; details in the Methods section). Logarithmically transformed statistically significant 
metabolite patterns, per cycle phase, meeting q value threshold q < 0.20 can be visualized in Fig. 3. Mean log 
intensity and individual variability of metabolites with 2 or more statistically significant contrast comparisons 
meeting q < 0.20 are depicted in Fig. 4.
Plasma amino acids and biogenic amines were significantly lower in the luteal phase. Out of the 
54 amino acids and derivatives and biogenic amines detected, 48 reached statistical significance (p-value < 0.05) 
in the 5 phase contrast comparisons: luteal-follicular (L-F), luteal-menstrual (L-M), luteal-periovulatory (L-O), 
premenstrual-luteal (P-L) and peri-ovular-menstrual (O-M) (Table 1 and Supplementary Table 1).
Ornithine, arginine, alanine, glycine, methionine, and proline were statistically significant in all 5 phase con-
trast comparisons, with the luteal phase showing a statistically significant reduction in amines relative to the other 
phases. After correction for multiple testing and using a q value threshold <0.20, 37 amines reached statistical 
significance in the L-M contrast. Nineteen of these same amines met the q value threshold <0.20 for the L-F, 4 for 
L-O and 9 for P-L (Table 2 and Fig. 4). Total glutathione was statistically significant only for L-F. Threonine, orni-
thine, and serine show significance across the 4 phase contrast comparisons; L-M, L-F, L-O, and P-L (q < 0.20) 
(Table 1 and Supplementary Table 2).
Figure 1. Hormone levels according to menstrual cycle phase. Changing concentrations of female sex 
hormones (progesterone, luteinizing hormone, follicular stimulating hormone, estradiol) that characterize the 
5 phases (menstrual, follicular, periovulatory, luteal and pre-menstrual) of the menstrual cycle (adapted with 
permission7). Follicular stimulating hormone concentration changes overlayed9.
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Analysis of the same amino acids and biogenic amines in urine yielded data for 60 compounds. Twenty 
amino acids were statistically significant (p < 0.05, Table 1) between phases for at least 1 phase contrast (L-F, 
L-M, L-O, O-M) with L-O and O-M having the highest number of statistically significant differences (Table 1 and 
Figure 2. Study schema. Thirty-four women (BMI 22.9 +/− 3.5 kg/m2, age 26.6 +/− 5.9 yrs) provided 4 blood 
and urine samples that each uniquely fit into 1 of 5 phase timepoints based on 4 sex hormone measurements 
(LH, FS, estradiol, and progesterone) and self-reported menstrual cycle timing. A total of 401 metabolites were 
measured which included 263 plasma, 114 urine, and 19 clinical and vitamin analyses. Metabolite profiling was 
conducted and statistically significant rhythmicity is depicted for the amino acid, lipid and organic acid panels. 
Biochemical pathway interconnectivity was identified between the urea cycle, 1 carbon metabolism, glutathione 
metabolism and the citric acid cycle. M-menstrual, F-follicular, O-Periovulatory, L-luteal, P-premenstrual phases.
www.nature.com/scientificreports/
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Figure 3. Metabolites vary across menstrual cycle phase. This heatmap with color gradients indicates 
rhythmicity across the menstrual cycle. Lower amino acid and lipid metabolite concentrations are visualized 
in the luteal phase. Phase means of logarithmically transformed metabolite data are row standardized in the 
heatmap to obtain Z scores. Two cells that are close in color represent similar Z scores, ranging from blue 
(Z equals minus 2) to red (Z equals plus 2). Amino acid, lipid, organic acid and sex hormone variables are 
ordered according to main biochemical pathways or classes and depicted at q < 0.20 after contrast analyses. 
Menstrual (M), Follicular (F), Periovulatory (O), Luteal (L), Premenstrual (P) phases are depicted. LPC- 
Lysophosphatidylcholine, LPE- Lysophosphatidylethanolamine, PC-phosphatidylcholine.
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Supplementary Table 1).Threonine differed in 3 comparisons and was the only amino acid that reached the FDR 
threshold in urine (q < 0.20 for L-O).
Plasma phospholipids were significantly reduced in the luteal phase. Of the 139 lipid species with 
detectable plasma levels, 57 reached statistical significance, (p-value < 0.05), for 1 to 5 phase contrast compar-
isons: L-F, L-M, L-O, P-L and O-M (specific p-values in Table 2). Thirty eight percent of the lipid species tested 
(53/139) consistently showed a statistically significant decrease in the luteal phase relative to the follicular and 
in some cases, relative to the menstrual phase (16/139) with 7 compounds showing a decrease in comparison to 
the premenstrual phase and 2 in comparison to the periovulatory phase. One compound, LPE 22:6, showed a 
statistically significant difference in 4 out of the 5 phase contrasts: L-F, L-M, L-O and P-L. After multiple testing, 
at q < 0.20, 17 lipid species met this threshold for L-F including 6 LPCs, 10 PCs and 1 LPE. One other LPC met 
this threshold for O-M (Table 2 and Supplementary Table 2).
Vitamin D and pyridoxic acid increased in the menstrual phase. Nineteen clinical parameters were 
tested including eight B vitamins, cofactors and metabolites. C reactive protein (CRP) was statistically significant 
in L-F (p < 0.05), while high density lipoprotein (HDL), triglycerides and cholesterol were statistically signif-
icant in L-F (p < 0.05). Glucose showed rhythmicity with a statistically significant decrease in the luteal phase 
in comparison to menstrual, pre-menstrual and periovulatory phases (p < 0.05). Magnesium showed a statisti-
cally significant decrease in L-M and O-M and riboflavin showed a statistically significant decrease in luteal vs. 
Figure 4. Amino acid variability by cycle phase. Mean log intensity is depicted along with individual variability 
for threonine, ornithine, arginine, alanine, glycine, serine, methionine, asparagine, proline, glutamine, tyrosine, 
gamma-glutamyl-alanine, citrulline, o-acetyl-serine, alpha-aminobutyric acid, and gamma-glutamylglutamine 
at one time point for each of the 5 menstrual phases (M = menstrual, F = follicular, O = periovular, L = luteal, 
p = premenstrual). Each colored line represents an individual. Amino acids are depicted which have 2 or more 
contrast comparisons meeting the multiple testing threshold of q < 0.20. Statistically significant luteal phase 
reductions can be observed.
www.nature.com/scientificreports/
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Biomarkers vs. Phase contrasts
Effect Size** FDR q****
L-F* L-M L-O P-L O-M q L-F q L-M q L-O q P-L q O-M
Sex Hormones, serum
Progesterone (ng/L) 2.88 2.80 2.30 −1.51 0.50 0 0 0 2.00E-11 7.87E-02
Estradiol (pmol/L) 0.94 1.79 −0.10 −1.19 1.89 1.32E-09 0 2.88E-08 0
Follicular stimulating hormone (FSH) (IU/L) −0.75 −0.80 −1.16 0.42 0.36 0 0 0 1.37E-03 3.52E-03
Lutenizing hormone (LH) (IU/L) −0.27 0.00 −1.40 0.04 1.39 2.72E-01 0 0
Amines, plasma
Threonine −0.45 −0.59 −0.46 0.43 −0.13 6.73E-09 0 2.24E-05 1.67E-03
Ornithine −0.35 −0.47 −0.31 0.31 −0.16 2.12E-05 2.10E-11 4.67E-02 9.32E-02
Arginine −0.34 −0.47 −0.26 0.28 −0.21 5.51E-04 1.87E-08 3.47E-01 3.62E-01
Alanine −0.35 −0.45 −0.24 0.35 −0.21 3.93E-04 3.29E-08 4.59E-01 9.32E-02
Glycine −0.31 −0.40 −0.23 0.34 −0.17 4.36E-04 6.16E-08 3.71E-01 9.32E-02
Serine −0.26 −0.37 −0.25 0.28 −0.11 2.50E-03 9.20E-08 1.93E-01 1.01E-01
Methionine −0.25 −0.37 −0.22 0.28 −0.15 4.95E-03 9.20E-08 3.47E-01 1.01E-01
Asparagine −0.27 −0.37 −0.22 0.30 −0.15 2.89E-03 5.24E-07 4.52E-01 9.32E-02
Proline −0.21 −0.38 −0.18 0.29 −0.20 1.30E-01 1.57E-06 2.05E-01
Glutamine −0.24 −0.32 −0.21 0.24 −0.11 4.21E-03 2.58E-06 3.47E-01 1.94E-01
Tyrosine −0.18 −0.32 −0.12 0.25 −0.20 1.74E-01 1.32E-05 3.04E-01
γ-glutamyL-alanine −0.49 −0.51 −0.23 0.33 −0.28 3.93E-04 1.34E-05 7.02E-01
Citrulline −0.22 −0.31 −0.23 0.26 −0.09 2.11E-02 1.34E-05 3.47E-01 1.87E-01
Lysine −0.18 −0.32 −0.21 0.23 −0.11 2.26E-01 1.34E-05 4.59E-01 4.63E-01
O-AcetyL-serine −0.31 −0.33 −0.25 0.24 −0.07 5.51E-04 2.12E-05 2.90E-01 3.82E-01
α-aminobutyric acid −0.25 −0.37 −0.32 0.23 −0.05 4.81E-02 2.33E-05 1.74E-01 9.54E-01
Sarcosine −0.17 −0.32 −0.09 0.17 −0.23 3.69E-01 5.34E-05
Ethanolamine −0.11 −0.23 −0.07 0.11 −0.16 4.98E-04
γ-glutamylglutamine −0.34 −0.41 −0.28 0.22 −0.13 3.51E-02 7.35E-04
L-Isoleucine −0.14 −0.24 −0.08 0.16 −0.16 1.09E-03
Methoxytyrosine −0.20 −0.25 −0.16 0.21 −0.09 7.40E-02 1.17E-03 6.48E-01
Seroton −0.71 −0.57 −0.12 0.06 −0.46 1.17E-03 6.95E-03
Hydroxylysine −0.08 −0.22 −0.05 0.17 −0.17 1.53E-02
γ-aminobutyric acid −0.10 −0.22 −0.05 0.02 −0.17 1.58E-02
Valine −0.11 −0.21 −0.08 0.11 −0.13 1.66E-02
β-Alanine −0.05 −0.11 −0.06 0.09 −0.05 1.72E-02
4-hydroxy-proline −0.26 −0.32 −0.19 0.35 −0.13 2.42E-01 1.78E-02
Histidine −0.09 −0.19 −0.06 0.14 −0.13 3.89E-02
Homoserine −0.23 −0.24 −0.09 0.34 −0.15 1.61E-01 4.08E-02 1.49E-01
Phenylalanine −0.08 −0.19 −0.01 0.14 −0.17 4.79E-02
Leucine −0.07 −0.18 −0.05 0.09 −0.13 4.79E-02
Aspartic acid −0.15 −0.28 −0.07 0.10 −0.21 1.00E-01
Tryptophan −0.08 −0.18 −0.05 0.10 −0.13 1.06E-01
Methionine sulfone −0.14 −0.17 −0.09 0.16 −0.08 1.12E-01
3-aminoisobutyric acid −0.07 −0.19 −0.21 0.11 0.02 1.74E-01
2-aminoadipic acid −0.06 −0.18 −0.05 0.10 −0.14 1.91E-01
Glutathione −0.33 −0.01 0.00 0.01 −0.02 1.61E-01
Assymetric-dimethyl-arginine (ADMA) −0.08 −0.14 −0.22 0.03 0.08 1.96E-01 2.36E-01
Amines, urine
Threonine −0.29 −0.40 −0.54 0.19 0.14 3.54E-01 1.79E-01
Table 1. Measured sex hormone (progesterone, estradiol, follicular stimulating hormone, lutenizing hormone) 
and 39 amino acid effect sizes and q values are listed for all significant phase comparison categories. *Luteal/
follicular (L-F), luteal-menstrual (L-M), luteal-periovulatory (L-O), premenstrual-luteal (P-L) and peri-ovular-
menstrual (O-M); **All results are based on natural log transformed data. Effect sizes are estimated phase-
phase differences (“contrasts”). ***Student’s t-test p-values of the contrasts are controlled for multiple testing 
within metabolites by Bonferroni and across metabolites using Benjamini-Hochberg FDR, resulting in q values 
as listed. Significant q values are in bold. Values above 0.50 are intentionally left blank.
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pre-menstrual phases. However, these results were not significant when corrected for multiple testing (q < 0.20). 
Vitamin D (25-OH vitamin D) showed significant decreases in L-F, L-M and O-M with L-M and O-M and met 
the multiple testing threshold q < 0.20). Moreover, the menstrual phase consistently showed higher levels of vita-
min D. Pyridoxic acid also showed an elevation in the menstrual compared to the periovulatory phases (q < 0.20, 
Table 2 and Supplementary Table 2).
Plasma and urine acylcarnitines showed a trend towards an increase in the periovulatory 
phase. Of the 50 compounds tested in the acylcarnitine panel, 19 were statistically significant (Table 2) in 
plasma and 16 statistically significant in urine (p < 0.05) (Table 2). The majority of plasma and urine metabolites 
were altered in O-M with an increase in the periovulatory phase. However, only urinary malonylcarnitine reached 
the q < 0.20 threshold for multiple testing (Table 2 and Supplementary Table 2).
Organic acids and endocannobinoids showed different patterns between phases. Sixteen 
organic acid metabolites had concentration levels above the respective limit of quantification in plasma out of 
Biomarkers vs. Phase contrasts
Effect Size** FDR q values***
L-F* L-M L-O P-L O-M q L-F q L-M q L-O q P-L q O-M
Vitamins
25-OH-vitamin-D - serum 
(nmol/L) −0.06 −0.09 0.01 0.00 −0.10 4.82E-01 1.21E-02 3.85E-02
Pyridoxic acid - plasma (nmol/L) 0.05 −0.16 0.29 0.18 −0.45 1.18E-01
Lipids, plasma
LPC 18:2 −0.26 −0.17 −0.08 0.22 −0.09 4.78E-04 2.89E-01
LPC 22:6 −0.20 −0.18 −0.09 0.17 −0.09 1.76E-02 2.89E-01
LPE 22:6 −0.34 −0.27 −0.21 0.27 −0.06 1.45E-02 2.89E-01
PC O-42:6 −0.13 −0.09 −0.06 0.10 −0.03 1.11E-02 9.34E-01
PC 40:8 −0.15 −0.07 −0.01 0.09 −0.06 2.41E-03
LPC 18:3 −0.30 −0.09 0.02 0.26 −0.11 1.76E-02
PC O-34:3 −0.14 −0.02 −0.09 0.09 0.08 2.64E-02
LPC 16:1 −0.20 −0.11 −0.02 0.05 −0.08 1.76E-02
PC 34:3 −0.19 −0.02 −0.04 0.10 0.02 3.30E-02
LPC 20:3 −0.16 −0.07 0.02 0.07 −0.10 3.83E-02
LPC 20:4 −0.17 −0.12 −0.06 0.12 −0.06 1.76E-02
PC O-38:7 −0.09 −0.02 −0.04 0.11 0.02 7.74E-02
PC 34:2 −0.08 −0.02 −0.06 0.02 0.03 3.30E-02
PC 32:2 −0.26 −0.19 −0.05 0.17 −0.14 3.30E-02
PC 36:2 −0.09 −0.02 −0.02 0.03 0.00 9.41E-02
PC 36:4 −0.08 −0.01 −0.04 0.03 0.02 1.26E-01
PC O-36:5 −0.13 −0.03 −0.07 0.10 0.04 1.26E-01
LPC 18:0 −0.11 −0.11 0.08 0.03 −0.19 4.78E-01 1.60E-01
Acylcarnitines, urine
Malonylcarnitine −0.18 0.18 −0.43 0.19 0.61 1.96E-01
Organic Acids, plasma
Inositol −0.20 −0.30 −0.40 0.30 0.10 9.53E-02 9.62E-02 1 1
Pyroglutamic acid −0.14 −0.39 −0.46 0.23 0.07 2.11E-02 9.62E-02
Methylmalonic acid −0.12 −0.18 −0.13 0.06 −0.04 9.53E-02
Organic Acids, urine
Uracil 0.27 0.39 −0.23 −0.28 0.61 4.11E-01 3.74E-02
Succinic acid −0.03 0.26 −0.30 0.07 0.57 9.67E-02
Citric acid 0.00 0.17 −0.16 −0.03 0.33 1.80E-01
Endocannabinoids, plasma
Linolenoylethanolamide (LEA) −0.15 −0.08 −0.11 0.02 0.03 1.92E-02
Table 2. Measured vitamins (25-OH-vitamin D, pyridoxic acid),lipids (7 LPC, 1 LPE, 10 PC), malonylcarnitine, 
plasma organic acids (inositol, pyroglutamic acid, methylmalonic acid), urine organic acids (uracil, succinic 
acid, citric acid) and linolenylethanolamide are listed for all significant phase comparison categories. *Luteal/
follicular (L-F), luteal-menstrual (L-M), luteal-periovulatory (L-O), premenstrual-luteal (P-L) and peri-
ovular-menstrual (O-M); **All results are based on natural log transformed data. Effect sizes are estimated 
phase-phase differences (“contrasts”). ***Student’s t-test p-values of the contrasts are controlled for multiple 
testing within metabolites by Bonferroni and across metabolites using Benjamini-Hochberg FDR, resulting 
in q values as listed. Significant q values are in bold.Values above 0.50 are intentionally left blank. LPC, 
Lysophosphatidylcholine, LPE- Lysophosphatidylethanolamine, PC-phosphatidylcholine.
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which 10 reached statistical significance, p < 0.05. Inositol, pyroglutamic acid and methylmalonic acid reached 
the multiple testing threshold (q < 0.20) for L-M for all 3 metabolites and L-O for inositol and pyroglutamic acid.
Twenty-three organic acid metabolites were analyzed in urine, of which 14 were statistically significant, 
p < 0.05, in various contrasts. Uracil, succinic acid and citric acid reached the multiple testing threshold q < 0.20 
for O-M (Table 2 and Supplementary Table 2).
In plasma, 19 endocannabinoids had detectable levels, of which 5 demonstrated statistical significance 
p < 0.05 across L-F, L-M, L-O, and O-M; and LEA reached statistical significance for L-F,L-M and L-O and met 
the multiple testing threshold (q < 0.20) for L-F (Table 2 and Supplementary Table 2).
Metabolite reactions and subsystems analyses demonstrated interconnectivity and differen-
tiation between menstrual cycle phases. The KEGG database and Human RECON model were used 
to enrich functional understanding of the 71 compounds that met the multiple testing q-value (<0.20). KEGG 
currently maps 18,111 metabolites to 519 pathways and RECON 2.2 uses 5324 metabolites and 7785 primarlly 
intracelluar reactions. Sixty-two of the 71 compounds in this study were identified in the KEGG pathways and 41 
of these 62 entitites (Supplementary Table 3) could be mapped in RECON 2. These 41 metabolites participate in 
1213 reactions (out of the 7440 reactions tabulated). We do not consider the 710 reactions for extracellular trans-
port and the 84 reactions for exchange/demand. Thus, 419 reactions remained for further analysis and interpre-
tation. Metabolite subsystem analyses of the 41 metabolic entities in the 419 reactions identified showed reduced 
glutathione, succinate, L-histidine and glycine followed by L-lysine, L-alanine, L-arginine and L-serine impact or 
are impacted by the most number of metabolic reactions (Supplementary Fig. 2A).
The 34 impacted sub-systems in the metabolic landscape include amino acid metabolism/synthesis; such 
as glutathione metabolism and the urea cycle; eicosanoid metabolism; citric acid cycle and bile acid synthesis. 
(Supplementary Fig. 2b) show the global, significant impact of changes in menstrual phase on metabolism.
A deeper pathway analysis in which interconnected, amino acid phase contrasts were compared, revealed 
minor differences between the 2 significant phase contrast categories. The luteal menstrual contrast did not show 
a significant difference in glutathione levels like the luteal follicular contrast (Supplementary Fig. 3).
Discussion
The present study demonstrates the rhythmic synchronicity of the menstrual cycle with healthy metabolism. 
Using deep molecular phenotyping of 5 menstrual cycle phases, paired with sex hormone rhythmicity, 67 bio-
chemical species of amino acid, lipid, carbohydrate, energy and vitamin metabolism significantly changed 
between phases; particularly, with a decrease in the luteal relative to menstrual and follicular phases (Fig. 3). 
Much fewer changes were observed in the urine in comparison to the plasma. These biochemical species com-
prise major biochemical pathways which impact physiological functioning and may increase vulnerability to 
sex-hormone related disorders, such as PMS, PMDD, and polycystic ovarian syndrome (PCOS).
Luteal phase protein, lipid, steroid, endometrial biosynthesis and increased energy utilization may lead 
to reduced biomarkers relative to menstrual and follicular phases. The decrease in amino acid plasma levels 
observed in the luteal phase, particularly in comparison to the menstrual phase, may be associated with proges-
terone’s upregulation of cell cycle progression and growth and the associated protein biosynthesis required for 
endometrial thickening to prepare the uterus for pregnancy8 (Table 1 and Figs 3 and 4). The decreased amino acid 
concentrations that participate in the urea cycle (arginine, ornithine and citrulline) suggest reduced ammonia 
waste in the luteal phase, which supports progesterone’s anabolic amino acid use (Fig. 5). Sex hormone regulation 
of nitrogen utilization through nitrogen excretion fluctuation20,24 and reduced concentrations of amino acids in 
the luteal phase suggest the intake of a higher protein load might, in certain instances, be advantageous to support 
additional nitrogen needs. Women have higher energy expenditure and compensate by eating more in the luteal 
phase, particularly protein; suggesting the anabolism in this phase could be greater than the degree of difference 
we observe using the tested metabolomics technologies25,26.
The anabolic effect of the luteal phase does not appear to be limited to amino acids, as certain lipids decreased 
in the luteal relative to follicular phases suggesting a higher utilization of fat for lipid or steroid synthesis, and/
or an increase in fat absorption with less need for anabolism in the follicular phase (Table 2 and Fig. 3). Previous 
research demonstrates total phospholipid content of the endometrium is increased in the luteal phase by 26% 
relative to the periovulatory time-period27. A 10-fold increase of phospholipase A2 in endometrial tissue has 
previously been identified in the luteal phase28. Partial hydrolysis of phosphatidylcholines (PC) and phosphati-
dylethanolamines (PE) by phospholipase A2 produces lysophosphatidlycholines (LPC) and lysophosphatidlyeth-
anolamines (LPE). PE and LPC are minor phospholipids found in cell membranes such as myelin sheaths and 
erythrocytes; playing roles in cell signaling and enzyme activation. Our findings of decreased PCs, LPCs, PEs and 
LPEs are consistent with their anabolic use for endometrial tissue thickening for pregnancy preparation during 
the luteal phase. Previous research identified PCs, LPCs and LPEs are further reduced in the luteal phase of PCOS 
patients versus healthy controls29,30. Thus, lower phospholipids in the luteal phase could be physiologically nor-
mal. However, certain diseases may perturb this state further, suggesting augmentation of physiologic vulnerabil-
ity and highlighting the importance of studying hormonal rhythmicity in health and disease.
Endocannabinoids are known to interact with sex hormones and cytokines to regulate fertility31. Conversely, 
changes in levels of sex hormones are known to alter endocannabinoid signaling32. The central nervous sys-
tem is a rich source of endocannabinoids, highly sensitive to inflammation and this interaction is implicated in 
PMDD33. Additionally, endocannabinoids are generated from membrane phospholipids31,34. In the present study, 
one endocannabinoid, linolenoyl ethanolamide (LEA), demonstrated luteal phase rhythmicity, which has not 
been demonstrated previously (Table 2). The low concentration of LEA observed may be a result of phosphoti-
dylethanolamine use for endometrium development. This results in less LEA available for endocannabinoid gen-
eration. Further research is needed to identify if this can increase vulnerability to a sub-optimal stress response 
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in individuals susceptible to PMS or PMDD, particularly when combined with low concentrations of amino acid 
precursors of neurotransmitter metabolism.
Medium and longchain acylcarnitines are formed from fatty acid oxidation, and elevated in inflammation, 
menopause and lower in PCOS35,36. In our healthy, premenopausal population, a trend of upregulated acylcarni-
tines was observed in the periovular phase from urine and plasma which may reflect a higher state of inflamma-
tion and demand for beta oxidation and energy utilization37 (Supplementary Table 2).
Clinical laboratory diagnostics used in practice can vary with the menstrual cycle due to increased anabolic 
demands in the luteal phase, for example, and should be interpreted with caution. Cholesterol is a key constituent 
of sex hormones and is utilized during the luteal phase for progesterone and estrogen synthesis. In the present 
study, cholesterol and HDL showed significant trends with reductions in the luteal relative to the follicular phases 
and, consistent with prior literature38,39. Triglyceride concentrations are known to be reduced in the luteal phase, 
as was observed in our study; and, more specifically, are reduced 30% from estradiol treatment (but not progester-
one) due to accelerated VLDL-TG plasma clearance40,41. Thus, caution is warranted when interpreting cholesterol 
and triglyceride laboratory results (Table 2).
While not yet accepted as a biomarker for clinical practice, inositol is produced by the human body from 
glucose and may be in high demand to meet the anabolic requirement of luteal phase pregnancy preparation. 
It plays a key role in insulin signal transduction, lipid transport and catabolism, oocyte maturation, embryonic 
development and cytoskeleton assembly which influences the steroidogenesis process42–44. We observed a signifi-
cant reduction in luteal phase myo-inositol (Table 2). The trend observed of reduced glucose concentration in the 
luteal phase may have led to the reduction in inositol production (Supplementary Table 2).
Significant neurotransmitter, amino acid and B vitamin precursor rhythmicity may influence susceptibility to 
the cyclical stress, anxiety and depression implicated in PMS and PMDD. Women are more affected than men by 
depressive disorders during the time between menarche and menopause suggesting this increase in depression 
risk is sex hormone related45–47. For example, γ-amino-butyric-acid (GABA) inhibition has been implicated in 
depression pathophysiology, differs between men and women, and can be modulated by progesterone and estro-
gen48,49. We have observed a significant reduction of the neurotransmitter serotonin and several neurotransmitter 
metabolic precursors (tyrosine, tryptophan, 3-methoxytyrosine, GABA, L-phenylalanine) which is consistent 
with previous research that demonstrates reduced mood enhancing neurotransmitter metabolite levels in the 
luteal phase, such as, 5-hydroxyindoleacetic acid (5-HIAA), the serotonin metabolite50 (Table 1, and Fig. 5).
Four-pyridoxic acid is one of two major vitamin B-6 compounds present in plasma. It is a cofactor in sex 
hormone gene expression and neurotransmitter metabolism through the conversion of tryptophan to seroto-
nin51. It is also a cofactor for GABA synthesis (Fig. 5). Supplementation with B6 has been shown to improve the 
Figure 5. Rhythmic metabolites in the urea cycle, neurotransmitter metabolism connect with 1 carbon, 
glutathione metabolism and the citric acid cycle. The metabolites with FDR controlled rhythmicity 
participate in inter-related, biochemical pathways including nitrogen metabolism (the urea cycle), 
neurotransmitter metabolism, methylation (1 carbon metabolism), oxidative stress (glutathione metabolism) 
and energy metabolism (citric acid cycle). NOS = Nitric oxide synthase; BH4 = Tetrahydrobiopterin; 
BH2 = Bihydrobiopterin; MTHFR = Methylenetetrahydrofolate reductase; THF = Tetrahydrofolate; 
MTR = Methionine synthase; DMG = Dimethylglycine; TMG = Trimethylglycine; B6 = Vitamin B6. 
Compounds boxed with dotted lines (NOS, BH4, BH2, MTHFR, THF, MTR, 5-methyl THF, DMG, TMG, 
homocysteine) were not evaluated or not significant (dopamine). All metabolites without dotted lines met the 
multiple testing threshold q < 0.20. *Cystathionine was statistically significant with p value < 0.05, but did not 
meet the multiple testing threshold.
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psychiatric symptoms of PMS52,53. In our study, 4-pyridoxic acid was significantly lower in the periovulatory 
phase, which may increase susceptibility to premenstrual syndrome in vulnerable individuals should there be 
insufficient B6 for tryptophan to serotonin conversion in the brain (Table 2). The periovulatory reduction in 
4-pyridoxic acid may lead to the cystathionine depletion observed in the luteal phase as B6 is a cofactor for the 
cystathione-β−synthase conversion to cystationine (Table 2 and Fig. 5).
Rhythmicity in glutathione and associated metabolites may lead to oxidative stress and impaired liver detox-
ification and may be associated with sex hormone influences in oxidative stress and drug metabolism54–56. Sex 
hormones have been shown to be correlated with redox balance during the menstrual cycle in the endometrium 
through modulation of glutathione metabolism57. In the present study, plasma total glutathione and its’ precur-
sors; glycine, γ- glutamyl-alanine, and pyroglutamic acid showed significant differences across the menstrual 
cycle with the precursors following the same pattern of lowest concentrations in the luteal phase (Table 1 and 
Fig. 5). In the present study, the reduced glutathione precursors in the luteal phase significantly increased in 
the menstrual phase, which may be necessary to precede glutathione’s successful follicular phase regeneration 
(Supplementary Fig. 3). Previous findings correlate elevated glutathione and glutathione peroxidase activity with 
the estrogen peak in the follicular phase58–60; and may be one mechanism through which estrogens attenuate oxi-
dative stress61,62. Individuals with PMS have been shown to have an imbalance in oxidant/antioxidant status and 
may be more susceptible in a state of low glutathione metabolic activity in the luteal phase63.
Vitamin D supplementation, when combined with calcium, has been used to improve weight loss, menstrual 
regularity, hyperandrogenism and, possibly, fertility; in women with PCOS64. High dietary intake of vitamin D 
may reduce risk of PMS which may be related to its capacity to activate serotonin synthesis65,66. Vitamin D regu-
lates calcium and bone health, sex steroidogenesis, and interacts with progesterone to regulate the immune sys-
tem through T cell induction of the vitamin D receptor67. A reduction of 25-hydroxyvitamin D (25OH-vitamin 
D) associated with a decrease in estradiol is seen in post-menopause and likely related to the sensitive interde-
pendency between changes in estrogen levels and vitamin D binding protein68. In human follicular cells, it alters 
FSH sensitivity and participates in folliculogenesis and progesterone production, indicating a possible role in 
follicular development and luteinization69. In our study, the significant reduction of vitamin D in the luteal and 
periovulatory phases may reflect a higher utilization for folliculogenesis in the periovulatory phase and progester-
one synthesis during the luteal phase, which has been suggested in prior research70 (Table 2).
Fatty acids contained in the phospholipids found reduced in the luteal phase of the present study participate in 
inflammation modulation through eicosanoid signaling, including linoleic (18:2,ω6), docosahexaenoic (22:6,ω3), 
stearic (18:0ω6), linolenic (18:3,ω6), arachidonic (20:4,ω6), acids (Table 2). It has been suggested conversion of 
linoleic to γ-linolenic acid is reduced in PMS71. Thus, a state of low linolenic acid could be further augmented in 
the luteal phase in individuals susceptible to PMS leading to inflammation72. PMS symptoms related to inflam-
mation include mood, abdominal cramps, back pain, breast tenderness, appetite cravings, weight gain and bloat-
ing73. Symptoms of PMS are associated with elevated CRP, which was also observed in the luteal phase73; and the 
elevated luteal phase acylcarnitines may also potentiate a hyperinflammatory state35.
Health can be defined as the ability of a living being to adapt and to self manage74. The healthy, physiologic 
state of rhythmicity must be defined to understand the perturbations that need adaptation and management. 
Identification of biochemical variations in a healthy menstrual cycle can provide a foundation of comparison 
for future deep phenotyping, such as phenotypic challenges of adaptation75,76, for sex hormone related disorders, 
such as PMS, and PMDD.
This data obtained from healthy women highlights the importance of deeper research on metabolism and sex 
hormone rhythmicity to understand how therapeutic strategies could be developed to treat challenging medical 
conditions such as PMS and PMDD. Perturbations in rhythmicity caused by diet, stress and environmental tox-
ins may impact sex hormone related health challenges and result in a loss of rhythmicity and, thus, therapeutic 
strategies, such as dietary change, may be optimal for restoration. The dietary implications of this study’s findings 
deserve further testing in a population vulnerable to insufficient diet intake to sustain healthy rhythmicity such 
as the large population of women with symptoms of PMS and PMDD. Higher protein load, phosphatidylcholine, 
omega 377 and omega 672 fatty acid intakes may be implicated in the luteal phase along with assurance of sufficient 
vitamin D intake65/sun exposure, B678 sulfur containing vegetables to promote glutathione metabolism79, and 
antioxidant food sources63 intake throughout the cycle.
The following summarizes the key limitations in our study. Dietary intake has a significant impact on metab-
olomics results80. While participants limited tea, coffee, fish, alcohol and vigorous exercise 24 h prior to sam-
pling81; dietary data were not collected throughout the cycle to assess the associations between differences in food 
intake and biochemical changes in the blood, plasma and urine. This study was limited in its capacity to detect 
significant vitamin differences due to missing values from limited sample volumes. In order to develop effective, 
sensitive diagnostics using metabolomics technologies, more time point measurements could enhance the gran-
ularity of conclusions about biochemical changes. Participants were excluded if they were diagnosed with a health 
condition, however, women who may have had recurrent PMS symptoms in the setting of a healthy menstrual 
cycle, insufficient to necessitate a medical diagnosis, may not have been excluded.
Our study is, to the best of our knowledge, the first of its kind to conduct a deep phenotyping of the metabolo-
mic, lipidomic, and nutrient biomarker differences across menstrual cycle phases in healthy women. Significant 
changes in levels of several amino acid and lipid metabolites were identified in addition to those characterized 
previously19. Amino acid and lipid metabolites were reduced in the luteal phase, suggesting differences in ana-
bolic requirements related to changing hormone levels. Rhythmic differences in neurotransmitter related amino 
acid precursors, vitamin cofactors and stress related metabolites may influence predisposition for anxiety and 
depression related PMS or PMDD. Glutathione and associated amino acid precursors show rhythmic differ-
ences suggesting a greater propensity for oxidative stress throughout the menstrual cycle. The reduction of amino 
acid levels in the luteal phase combined with prior research on cyclical nitrogen fluctuation, increased energy 
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metabolism and food intake may suggest the intake of a higher protein load as a portion of the increased calorie 
intake would be advantageous. A menu plan that optimizes protein intake, B6, omega 3 and omega 6 fatty acid 
and glutathione metabolism deserves further testing in a population at risk of PMS or PMDD. The information 
generated from this study provides the foundation for research on differences in menstrual cycle, sex hormone 
related metabolism and clinical biomarker interpretations. Furthermore, it forms the basis to test novel nutrition 
strategies for women with an emphasis on health issues impacted by rhythmic variability.
Methods
Study design. All methods were performed in accordance with the relevant guidelines and regulations. 
Ethical approval was received from both the Research Ethics Committee, University College Dublin (UCD) and 
the Commission Cantonale D’Ethique de la Recherche sur L’Etre Humain (CER-VD) in Switzerland. All partic-
ipants provided written informed consent before study participation. Participants visited the clinic at 4 different 
timepoints for blood and urine collection at different menstrual cycle phases (Fig. 2). Participants were instructed 
to keep a menstrual calendar for 1 month prior to sample collection in order to estimate the length of their cycle. 
Using a guide for menstrual phase length19, urine and blood samples were collected from each woman at 4 dif-
ferent time points in one menstrual cycle; estimated to represent 4 stages of the menstrual cycle: menstrual, folli-
cular, luteal and premenstrual (Fig. 1). Participants were instructed to use a luteinizing hormone (LH) urine dip 
strip test kit (Medimpex Ltd Inc) at home in order to determine the date of ovulation. Following serum hormonal 
analysis, classification of the phases was refined to define 5 stages of the menstrual cycle (menstrual, follicular, 
periovulatory, luteal and premenstrual)19.
Study participants. Thirty four healthy, premenopausal women at UCD, Dublin with a mean age of 26.6 
years, standard deviation (SD) of +/−5.9; and a mean body mass index (BMI) (Kg/m3) of 22.9 +/− 3.5 volun-
teered to participate in the study. Participants were excluded with a BMI <18 or >30 Kg/m3, iron deficiency ane-
mia (hemoglobin <11.5 g/dl), diagnosis with a medical condition and use of prescribed medication or hormonal 
contraceptives (Fig. 2).
Blood and urine collection. Prior to blood and urine collection, participants were instructed to fast for 
12 h, limit tea and coffee consumption and abstain from fish, alcohol and vigorous exercise for 24 h. On the morn-
ing of collection, volunteers collected their first void urine at home in a chilled graduated container and then 
immediately delivered it to the laboratory on ice. Sample processing and serum hormone analyses were measured 
at the Biochemistry Department, National Maternity Hospital, Dublin, as previously described19.
Metabolite profiling analysis. Metabolite profiling was done by the Biomedical Metabolomics Facility, 
Leiden University, Leiden, The Netherlands. All samples (plasma and urine) were randomized and analyzed in 
batches, which included calibration lines, quality control (QC) samples and blanks. QC samples were prepared 
from pooled plasma and urine available in the laboratory and were analyzed every 10 samples for data quality 
and instrument response correction. Blank samples were used to correct for background signal and in-house 
developed algorithms were applied using the pooled QC samples to compensate for time-dependent drifts of the 
sensitivity of the mass spectrometer. Data was reported as ratio of analyte signal to internal standard.
The amine platform analyzed 74 amino acids and biogenic amines in plasma and urine using liquid chroma-
tography coupled to a mass spectrometer (LC-MS) employing an AccQ-Tag derivatization strategy adapted from 
the protocol supplied by Waters (Etten-Leur, The Netherlands)82. One μL of the reaction mixture was injected 
into the ACQUITY UPLC System (Waters, Etten-Leur, The Netherlands) on an AccQ-Tag Ultra column (Waters) 
for chromatographic separation coupled to a triple quadrupole mass spectrometer (AB SCIEX Qtrap 6500, 
Framingham, MA USA). Acquired data were evaluated using MultiQuant Software for Quantitative Analysis (AB 
SCIEX, Version 3.0.2). After quality control correction83, 54 plasma amines and 60 urine amines complied with 
the acceptance criteria of RSDqc <15%.
The lipid platform analyzed 185 compounds in 9 lipid classes in plasma using LC-MS as described84. 
Chromatographic separation was achieved on a ACQUITY UPLC™ (Waters, Etten-Leur, The Netherlands) with 
a HSS T3 column which was coupled to a ESI-Q-TOF (Agilent 6530, Jose, CA, USA) using reference mass cor-
rection84. The raw data were pre-processed using Agilent MassHunter Quantitative Analysis software (Agilent, 
Version B.04.00). After QC and blank correction, 139 compounds comply with the acceptance criteria RSDQC 
<30% and blank effect <40%. Twenty six organic acids were analyzed in urine by gas chromatography cou-
pled to mass spectrometry (GC-MS). After QC correction and considering blank effects, 23 urinary and 16 
plasma organic acids compounds complied with the acceptance criteria RSDQC <30% and blank effect <20%. 
The plasma and urine metabolites were measured by gas chromatography on an Agilent Technologies 7890A 
equipped with an Agilent Technologies mass selective detector (MSD 5975C) and MultiPurpose Sampler (MPS, 
MXY016-02A, Gerstel, Germany). Chromatographic separations were performed on a HP-5MS and detected 
using a quadrupole mass spectrometer. The raw data were pre-processed using Agilent MassHunter Quantitative 
Analysis software (Agilent, Version B.05.01).
The endocannabinoid profiling platform analyzed 24 compounds in plasma, as previously described85. 
Chromatographic separation was achieved by an ACQUITY UPLC System (Waters, Etten-Leur, The Netherlands) 
on an ACQUITY UPLC HSS T3 Column. The UPLC was coupled to electrospray ionization on a triple quadru-
pole mass spectrometer (AB SCIEX Qtrap 6500, Framingham, MA USA). Acquired data were evaluated using 
MultiQuant Software for Quantitative Analysis (AB SCIEX, Version 3.0.2). After quality control correction 19 
endocannabinoids complied with the acceptance criteria of RSDqc <15%.
The acylcarnitine platform analyzed 45 acylcarnitines as well as trimethylamine-N-oxide, choline, betaine, 
deoxycarnitine and carnitine in plasma and urine. Chromatographic separation was achieved by UPLC (Agilent 
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1290, San Jose, CA, USA) on an AccQ-Tag Ultra column (Waters, Etten-Leur, The Netherlands) coupled to elec-
trospray ionization on a triple quadrupole mass spectrometer (Agilent 6460, San Jose, CA, USA). Acquired data 
were evaluated using Agilent MassHunter Quantitative Analysis software (Agilent, Version B.05.01). After QC 
correction, 25 urinary and 27 plasma acylcarnitines complied with the acceptance criteria of RSDqc <15%.
The method validation used for the metabolite profiling fits with the acceptance criteria for precision (15% 
RSD, 20% RSD near LLOQ and accuracy (bias within +/−15% of the accepted reference value, within 20% near 
LLOQ) specified by the Conference Reports have been widely accepted in bio-analysis86. Recommended guide-
lines were followed for most metabolites, however, some were accepted which were close to the LOQ.
Clinical and vitamin biochemistry. Standard clinical routine analysis of human serum samples was per-
formed by the Molecular Nutrition laboratory at NIHS. The applied Architect plus ci4100 platform from Abbott 
Laboratories (Lake Bluff, IL, USA), consists of a chemistry and an immunoassay module87. Glucose, insulin, vita-
min B12, holotranscobalamin, folate, 25-hydroxy vitamin D and cortisol were determined by chemiluminescent 
microparticle immunoassays (CMIA) while cholesterol, HDL, triglycerides, high sensitivity C-reactive protein 
(hsCRP), ceruloplasmin, copper and magnesium were analyzed using the ARCHITECT cSystems assays devel-
oped by Abbott Laboratories (Wiesbaden, Germany)87.
Plasma analysis was completed by Vitas Analytical Services, Oslo, Norway for B1 (thiamin and thiamin mond-
phosphate), B2 (FAD, FMN), and B6 (4-pyridoxic acid, pyridoxal 5 phosphate). The analysis was performed with 
an an Agilent LC-FLD 1200 system using a fluorescence detector (FLD). Separation of the analytes was achieved 
by a Phenomenex Kinetex® column (2.6 µm C18 100 Å 100 × 4.6 mm). Unknowns were calibrated against known 
standards from Sigma-Aldrich, and reported as nmol/l.
Data analysis. Univariate data analysis was used to evaluate changes in metabolite concentrations, clinical, 
and vitamin data (biochemical species) over five menstrual cycle phases. A mixed model approach was used in 
which all data was natural log transformed to meet normality assumptions.
In the analysis Yijt is the log transformed level of participant i in (1, .., 34) for biochemical species j in (1, .., 397) 
at menstrual phase t in (1, …, 5). Data were analyzed using the following Linear Mixed Model88.
μ ε= + +Y b (1)ijt ij jt ijt
The random intercept, σ~ ( )b N 0,ij jb , accounts for the dependence of observations from the same partici-
pant, μjt is the (mean biochemical species j) fixed effect in phase t and  σε~ N(0, )ijt j  is an independent, normally 
distributed error term.
Of interest are pairwise (phase-phase) differences, which we call “contrasts”, defined as μ μ− ′( )jt jt  where t and 
t’ represent two different phases, e.g. luteal and menstrual. The five phases yield ten unique pairwise differences 
per biochemical species j, delivering a total of 3970 (two-sided Student’s t-test) p-values, denoted pj
c for contrast 
c in (1, …, 10) in biochemical species j.
Multiple testing adjustments were made using Bonferroni within biochemical species by transforming pj
c to 
= ×p̂ pmin(10 , 1)j
c
j
c , and across biochemical species by controlling the false discovery rate contrast-wise using 
Benjamini-Hochberg (BH)89. For each contrast c we provide the BH procedure with the p̂j
c values of all biochem-
ical species from the same panel (amino acids, lipids, et cetera) and sample (plasma, urine, et cetera) resulting in 
a corresponding set of FDR controlled values qj
c. A pairwise difference c for metabolite j is considered significantly 
different from zero if < .q 0 20j
c . All biochemical species with at least one significant contrast are labeled as “enti-
ties” and studied further. This threshold is sufficiently liberal to ensure the consecutive pathway analysis is con-
ducted on a rich set of exploratory biochemical species. Result tables are provided so the reader may replicate 
conclusions using a more stringent threshold if needed (Supplementary Table 2). All statistical analyses were 
conducted in the R programming language (version R 3.4.0 for Windows) using packages lme4 (1.1–13), lmtest 
(0.9–35) and multcomp (1.4–6)90–92.
Metabolite reactions and subsystems analyses. The Human Genome Scale Metabolic Model or 
RECON 2.2.93–95 was used for overlaying the metabolite concentration data to map changes in metabolism at 
different phases to a global/systems scale. Metabolites were input into the RECON model using correspond-
ing KEGG identities96. Reactions in the RECON model were identified and filtered for those with meaning-
ful metabolic impact. Impacted metabolic subsystems were then identified based on participating reactions. 
Interconnectivities and differences between menstrual cycle phases were visualized using custom MATLAB 
(Mathwork Inc.) scripts and edited using yEd (yWorks GmbH)17,18,97–99. (Supplementary Figs 2a,b and 3).
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